Future studies should investigate the effects of decernotinib in stroke models associated with reperfusion as well as the impact of JAK3 inhibition on long-term outcomes in embolic stroke models with and without thrombolysis with recombinant tissue plasminogen activator. This evidence concerns the gene JAK3 and stroke disorder.